SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares and updating the evergreen provision, materially expanding the equity grant capacity available to officers and directors.
View raw filing on EDGAR →Xiao-I Corporation received a Nasdaq notification on August 6, 2026, that it failed to maintain the minimum market value of publicly held shares (MVPHS) of US$15,000,000 required under Nasdaq Listing Rule 5450(b)(3)(C). The company has been granted a 180-day compliance period (until February 1, 2027) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a material disclosure of delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →The 6-K discloses that on August 5, 2026, the board of directors resolved not to reappoint WWC, P.C. as independent accountants (effective immediately), and on August 6, 2026, engaged Edston Global PAC as the new independent registered public accounting firm. This is a clear auditor change. The filing explicitly states no disagreements or adverse opinions occurred during WWC's engagement, and no reportable events under Item 16F(a)(1)(v) of Form 20-F occurred, indicating a routine transition rather than a dispute-driven change.
View raw filing on EDGAR →Two executive officers resigned effective immediately: Graeme Shaw as Chief Technology Officer and Richard C. Davis as President. The filing explicitly discloses these departures under Item 5.02 and confirms no disagreements with the Company. The departure of a President is material to investors' assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →Churchill Capital Corp XIII consummated its IPO on August 3, 2026, raising $414 million in gross proceeds from the sale of 41.4 million units at $10.00 per unit, plus a concurrent $3.5 million private placement to the sponsor. While this is a capital-raising event, it does not fit neatly into the standard taxonomy: it is not an earnings release, M&A activity, debt issuance, or dilutive equity issuance (which typically refers to unregistered private placements). The IPO itself is a registered public offering of a blank-check company (SPAC), which is a material capital event but lacks a dedicated category. The disclosure emphasizes the trust account structure, the company's purpose to effect an initial business combination, and the audited balance sheet as of the IPO closing date.
View raw filing on EDGAR →The press release announces a 6-for-1 reverse share split approved by shareholders at a Special General Meeting on July 27, 2026, to be implemented after market close on August 12, 2026. While a reverse split is technically a capital restructuring rather than a traditional dividend, it is a return-of-capital event that materially affects share structure and is commonly classified under dividend_distribution in the absence of a dedicated reverse-split category. The announcement is material to investors as it affects share count, trading price, and potential delisting implications.
View raw filing on EDGAR →Alto Ingredients entered into an At-The-Market (ATM) Issuance Sales Agreement on August 5, 2026, authorizing the sale of up to $50.0 million in common shares. ATM offerings are a form of dilutive equity issuance that allows the company to raise capital opportunistically. The filing explicitly discloses the agreement with designated agents and the prospectus supplement filed under Rule 424(b), which are hallmarks of a registered equity offering. This is material to investors as it signals potential dilution and the company's capital-raising needs.
View raw filing on EDGAR →The exhibit discloses receipt of a NYSE letter notifying AMTD IDEA that it is below compliance standards due to ADS trading price falling below US$1.00 over a 30 trading-day period. The Company has a six-month cure period; failure to regain compliance will trigger NYSE suspension and delisting procedures. This is a direct delisting risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →iSpecimen Inc. entered into a placement agency agreement and securities purchase agreement on August 5, 2026, to issue and sell 996,231 shares of common stock and pre-funded warrants to purchase 2,849,923 additional shares for $5 million in aggregate proceeds. The offering closed on August 7, 2026, pursuant to a Form S-1 registration statement. This is a registered public offering of equity securities that is materially dilutive to existing shareholders and represents a significant capital raise for the company.
View raw filing on EDGAR →The 6-K announces the appointment of three independent directors (Chan Kelvin Zhi Hong, Lee Chee Wai, and Wong Khai Meng) effective August 5, 2026, with detailed biographies and committee assignments. While the filing also discloses three concurrent director resignations, the principal disclosed action is the appointment of new directors to the Board and reconstitution of board committees, which is material to investors' assessment of governance and board composition.
View raw filing on EDGAR →The Company entered into a Securities Purchase Agreement on August 7, 2026, establishing a $36 million commitment to fund pre-paid purchases over two years, with settlement through issuance of Class A Shares at 50% of market price (with a $0.10 floor). This is a dilutive equity issuance mechanism—a structured PIPE-like arrangement where the investor funds cash and the Company settles by issuing shares at a significant discount, creating substantial dilution to existing shareholders. The filing explicitly references a concurrent prospectus supplement for the offer and sale of Class A Shares.
View raw filing on EDGAR →HeartSciences received a Nasdaq notice on August 4, 2026, that it failed to comply with Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The company reported only $226,060 in stockholders' equity as of April 30, 2026, and does not meet alternative compliance metrics. Nasdaq has provided 45 days to submit a compliance plan, with potential delisting if the company fails to regain compliance. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses a delisting-related matter under Item 3.01. Although the outcome is favorable—Nasdaq confirmed on August 3, 2026 that the Company "timely evidenced compliance with the $1.00 bid price requirement and all other applicable criteria for continued listing"—the disclosure itself concerns a material delisting risk that was previously pending. The Company had been required to meet a $1.00 minimum bid price for 20 consecutive trading sessions by July 30, 2026, and this 8-K documents the resolution of that compliance challenge. This is material to investors as it addresses the registrant's continued listing status on Nasdaq.
View raw filing on EDGAR →The Audit Committee dismissed RBSM LLP and appointed Urish Popeck & Co, LLC as the Company's independent registered public accounting firm on August 4–5, 2026. This is a direct auditor change disclosed under Item 4.01. Although the prior auditor's reports contained no adverse opinions or disclaimers (except for a going-concern explanatory paragraph), the disclosure of material weaknesses in internal controls over financial reporting and the change itself are material to investors' assessment of audit quality and financial reporting reliability.
View raw filing on EDGAR →The 6-K discloses completion of a registered direct offering in which Nano-X sold 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants to a single institutional investor for approximately $8.0 million gross proceeds. This is a dilutive equity issuance under a registered shelf offering (Form F-3), meeting the definition of dilutive_issuance. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →Item 2.01 discloses the completion of a merger transaction on August 7, 2026, whereby USA Rare Earth, Inc. acquired Texas Mineral Resources Corp. through a two-step merger structure. The filing specifies the exchange ratio (0.043279843 shares of USAR Common Stock per TMRC share), the registration of the issuance under the Securities Act, and references the definitive Merger Agreement dated March 4, 2026. This is a material acquisition completion that would significantly affect investor assessment of the registrant's assets, capital structure, and strategic position.
View raw filing on EDGAR →This press release announces a 1-for-7 reverse share split approved by the Board on July 31, 2026, and previously authorized by shareholders at the November 14, 2025 Annual General Meeting. The reverse split is a governance/capital structure action that affects all shareholders' holdings and is material to investors assessing the company's capitalization and trading mechanics, though it does not fit the specific named governance categories (exec appointment/departure, compensation, shareholder vote results). The announcement also references a pending merger with MBody AI, but the primary disclosed action is the reverse split implementation.
View raw filing on EDGAR →The Board of Directors of Sun Life Financial Inc. declared dividends on common shares ($0.96 per share) and multiple series of preferred shares, all payable in Q3 2026. This is a routine but material dividend declaration that affects shareholders' returns and is customarily disclosed in a news release furnished as a 6-K exhibit.
View raw filing on EDGAR →The news release announces that Joseph Natale will succeed Scott Powers as Chair of the Board of Directors following Sun Life's Annual General Meeting in May 2027. While the release also discloses Powers' retirement, the principal disclosed action is Natale's appointment to the chair role—a material governance event for a major financial services company. The appointment of a new board chair is material to investors assessing leadership and governance quality.
View raw filing on EDGAR →The exhibit is a news release announcing Wheaton Precious Metals' Board declaration of a quarterly cash dividend of US$0.195 per common share for Q3 2026, representing an 18% increase from the prior-year quarter. The disclosure specifies the record date (August 20, 2026), payment date (September 3, 2026), and notes the dividend qualifies as an eligible dividend for Canadian tax purposes. This is a straightforward dividend declaration material to shareholders.
View raw filing on EDGAR →This news release announces completion of a key technical milestone in BTQ's multi-year collaboration with ITRI to validate the QCIM (Quantum Compute-in-Memory) architecture for post-quantum cryptography. The disclosure highlights successful validation of the core IP, demonstration of cryptographic acceleration across FIPS 203, 204, and 205 standards, and advancement to the next phase of module-level integration. While this is a product development and partnership milestone rather than a discrete M&A, financing, or governance event, it represents material progress toward commercialization of BTQ's core technology platform, reducing technical risk and supporting customer demonstrations and commercial partnerships—factors a reasonable investor would consider when assessing the company's ability to execute its business strategy.
View raw filing on EDGAR →This exhibit discloses the results of Nu Holdings' annual general meeting held on August 6, 2026, reporting shareholder votes on two proposals: approval of audited financial statements and the Annual Report on Form 20-F (99.88% in favor), and re-election of nine directors (96.23% in favor). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and is material as it confirms board composition and financial statement approval.
View raw filing on EDGAR →Petrobras's Board of Directors approved shareholder remuneration of R$ 17.4 billion (R$ 1.34814262 per share) to be paid in two installments in November and December 2026, comprising interest on equity and dividends. This is a material capital distribution to shareholders that would affect investor assessment of the company's capital allocation and cash return policy.
View raw filing on EDGAR →This 6-K furnishes a webcast presentation and operational highlights for Petrobras's 2Q26 performance, disclosing financial results including net income of US$10.4 billion, EBITDA of US$18.6 billion, and operating cash flow of US$12.3 billion, along with production records (3.34 MMboed) and operational metrics. The document explicitly references "2Q26 Performance" and presents quarterly financial and operational results comparable to a press release announcing earnings, making it an earnings_release rather than a periodic financial report.
View raw filing on EDGAR →This is Petrobras' condensed consolidated interim financial statements for the second quarter of 2026 (2Q26), prepared in accordance with IFRS Accounting Standards and reviewed by independent auditors. The document presents quarterly financial results including consolidated net income, operating cash flow, adjusted EBITDA, capex, and debt metrics—the core components of a periodic quarterly financial report. Although the filing includes operational highlights and management commentary, it is fundamentally a quarterly financial report itself, not a discrete earnings-release event.
View raw filing on EDGAR →This 6-K furnishes interim financial statements for Petrobras as of and for the six months ended June 30, 2026. The document includes parent company and consolidated statements of financial position, income, comprehensive income, changes in equity, cash flows, and added value, along with detailed notes. This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The filing is material as interim results are significant to investor assessment of the registrant's financial condition and performance.
View raw filing on EDGAR →The 6-K discloses a credit rating upgrade by Moody's Local AR, elevating EDENOR's long-term local and foreign currency ratings from "A.ar" to "AA-.ar" and affirming its equity rating. While a rating upgrade is a material financial event affecting the company's creditworthiness and cost of capital, it does not fit neatly into the discrete event taxonomy (not earnings, M&A, debt issuance, covenant breach, or impairment). The disclosure is material to investors assessing financial risk, but the event itself is external (a rating agency action) rather than a company-initiated transaction or operational change. Classified as governance_other as the closest fit for a material financial/governance event not otherwise categorized.
View raw filing on EDGAR →The Company announced a partial mandatory redemption of 37,237,014 Class "C" preferred shares (6.14% of outstanding) at R$53.71 per share (R$2 billion total) effective August 24, 2026, with corresponding ADS redemptions. While technically a redemption rather than a traditional dividend, this represents a return of capital to preferred shareholders and is material to investors holding these securities. The disclosure includes details on payment procedures, conversion options, and ADS delisting from NYSE to OTC markets, indicating significant capital distribution activity.
View raw filing on EDGAR →AXIA Energia announced the commencement of ADR trading on the OTC market and the filing of Form 15F to terminate its SEC registration and suspend reporting obligations under Section 12(g) of the Securities Exchange Act of 1934, with deregistration expected to become effective 90 days after filing. This constitutes a material delisting event — the company is voluntarily withdrawing from SEC reporting and transitioning to OTC trading, which materially affects investor access to regulated disclosures and the registrant's listing status.
View raw filing on EDGAR →EDENOR disclosed a credit rating upgrade by FIX SCR S.A. from "A+(arg)" to "AA-(arg)" with an Outlook revision from Stable to Positive. While this is a material event affecting investor perception of the company's creditworthiness and financial standing, it does not fit neatly into the standard event taxonomy. The disclosure is governance-adjacent (relating to external validation of financial health) but is fundamentally a financial/capital-markets event. Absent a more specific category for rating changes, governance_other is the best fit, though financial_other could also apply.
View raw filing on EDGAR →William List was appointed by the Board as Chief Financial Officer effective September 1, 2026, following Federal Housing Finance Agency non-objection. The disclosure centers on his appointment to this principal financial officer role, his compensation package (base salary of $432,957 and incentive award eligibility), and his background. While the filing also mentions Edward V. Weller's transition to Executive Senior Advisor, the principal disclosed action is List's appointment to the CFO position.
View raw filing on EDGAR →Under Armour issued a press release on August 7, 2026 announcing unaudited financial results for the first quarter of fiscal 2027 ended June 30, 2026, including revenue of $1.1 billion (down 3%), gross margin of 54.1%, net income of $1 million, and diluted EPS of $0.00. The company also updated its full-year fiscal 2027 revenue outlook to expect a mid-single-digit decline (versus prior slight decline) while maintaining profitability guidance. This is a standard quarterly earnings disclosure with material updates to forward guidance.
View raw filing on EDGAR →aTyr Pharma issued a press release on August 7, 2026 announcing second quarter 2026 financial results, including condensed consolidated statements of operations and balance sheets. The filing discloses Q2 2026 R&D expenses of $6.7 million, G&A expenses of $4.1 million, net loss of $10.3 million, and cash position of $58.9 million as of June 30, 2026. This is a standard quarterly earnings release furnished under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly financial results for Q2 2026 (ended June 30, 2026), including condensed consolidated balance sheets, statements of operations, and comprehensive loss. The Item 2.02 disclosure explicitly states "On May 8, 2026, Kiora Pharmaceuticals, Inc. (the 'Company') issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress," with the full press release attached as Exhibit 99.1. The filing includes detailed financial tables and operating metrics typical of an earnings announcement.
View raw filing on EDGAR →This is a clear earnings release disclosing Rapid Micro Biosystems' second quarter 2026 financial results. The Item 2.02 filing explicitly states the company "issued a press release announcing its financial results for its second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The disclosure includes detailed quarterly revenue ($8.1M, up 11% YoY), gross margin (15%, a record), net loss ($12.9M), and full-year 2026 guidance reaffirmation—all hallmarks of a standard quarterly earnings announcement.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the Fund's August 4, 2026 annual meeting. The filing reports final certified voting tallies for two proposals: (1) re-election of two Class I trustees (Bobby Majumder and Romano Tio, each receiving ~90% support), and (2) ratification of Cohen & Company, Ltd. as independent auditor (receiving 98.37% support). This is a textbook Item 5.07 disclosure of shareholder vote outcomes, material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →The filing discloses two executive appointments effective August 10, 2026: Andrew C. Wiechmann was appointed to serve as interim principal accounting officer (in addition to his CFO role), and Kristine Johnson was appointed as interim Global Controller. While the filing references a prior departure of the Global Controller and Chief Accounting Officer (disclosed March 31, 2026), the principal action disclosed here is the appointment of successors to fill those roles on an interim basis. The appointments of two officers to key accounting and financial reporting positions are material to investors' assessment of the company's financial controls and reporting infrastructure.
View raw filing on EDGAR →First Guaranty Bank entered into a Consent Order with the FDIC and Louisiana OFI effective August 7, 2026, following a September 2025 joint examination. The order imposes significant regulatory restrictions on capital maintenance (9% Tier 1 leverage, 14% total risk-based capital), credit extensions to classified borrowers, classified asset reduction timelines, loan review and underwriting standards, CRE concentration monitoring, and dividend restrictions. While the bank currently believes it is in compliance except for the Tier 1 leverage ratio (7.09% vs. 9% required), this is a material regulatory enforcement action that would affect investor assessment of the registrant's financial condition and operational constraints. This is a legal/regulatory event distinct from the specific categories (not a restatement, going concern, or material impairment), making it best classified as legal_other.
View raw filing on EDGAR →The filing discloses preliminary court approval of a settlement of consolidated shareholder derivative lawsuits against CorMedix and its officers/directors. The underlying claims allege breach of fiduciary duties related to false/misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath, resulting in a securities fraud class action and significant harm to the company. The settlement requires implementation of corporate governance reforms over 3.5 years, with potential attorneys' fees up to $3.9 million. This is a material litigation settlement with substantial corporate governance consequences.
View raw filing on EDGAR →EchoStar disclosed confidential management materials ("Cleansing Materials") prepared for discussions with holders of HSSC's 5.25% and 6.625% Senior Notes regarding potential debt transactions. The discussions failed to reach agreement, but the company is obligated under confidentiality agreements to publicly disclose the materials. While the disclosure involves debt obligations and potential restructuring discussions, the core event is the mandatory public release of previously confidential strategic and financial information under contractual obligation—a disclosure event that does not fit neatly into standard M&A, debt issuance, or covenant-breach categories. The materiality stems from the revelation of detailed business plans, financial projections, and strategic positioning to the market.
View raw filing on EDGAR →Dorchester Minerals disclosed quarterly financial results for Q2 2026 (period ended June 30, 2026) via press release dated August 6, 2026, reporting net income of $30,871,000 ($0.62 per common unit) and operating revenues of $56,075,000, with comparative results for Q2 2025 and year-to-date periods.
View raw filing on EDGAR →Dorchester Minerals adopted the Dorchester Minerals Operating LP Executive Severance Plan on August 6, 2026, establishing compensatory arrangements for designated executive officers including CEO Bradley J. Ehrman and CFO Leslie Moriyama, with severance benefits (cash payments, bonus acceleration, COBRA coverage, and equity vesting) triggered by qualifying terminations and enhanced benefits upon a Change in Control.
View raw filing on EDGAR →Gray Media issued a press release on August 7, 2026 reporting financial results for the three and six-month periods ended June 30, 2026, including revenue of $839 million (Q2) and $1,607 million (YTD), net income of $14 million (Q2) and net loss of $6 million (YTD), and Adjusted EBITDA of $214 million (Q2) and $368 million (YTD). The release also announces a new $250 million debt repurchase authorization. This is a standard quarterly earnings disclosure furnished under Item 2.02, material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →Gray Media's Board authorized a quarterly cash dividend of $0.08 per share payable on September 30, 2026, to shareholders of record on September 15, 2026. This is a straightforward dividend distribution disclosure, which is material to investors as it represents a return of capital and signals management's confidence in cash generation and capital allocation policy.
View raw filing on EDGAR →Nathan's Famous issued a press release on August 7, 2026 announcing financial results for its first fiscal quarter ended June 28, 2026, disclosing revenues of $54.1 million, net income of $8.8 million, and diluted EPS of $2.14 per share compared to prior-year results. The entire press release is attached as Exhibit 99.1 and incorporated by reference, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →The disclosure reports FDA feedback on an ANDA for preservative-free ketamine, including a first-round review with no drug-related major deficiencies but one packaging-related deficiency requiring clarification. The FDA has committed to expedited review given ketamine's status on the drug shortage list and strategic importance. This is a material regulatory milestone affecting the company's path to commercialization, but does not fit the specific categories of restatement, auditor change, going concern, impairment, litigation, or other named event types. It is clearly operational/regulatory in nature—a product development and regulatory approval milestone.
View raw filing on EDGAR →Geospace Technologies issued a press release on August 6, 2026, announcing operating results for Q3 fiscal year 2026, disclosing revenue of $15.8 million (down from $24.8 million year-ago), a net loss of $9.7 million or $(0.75) per diluted share (versus net income of $0.06 per share in Q3 2025), and nine-month results showing a net loss of $30.5 million or $(2.37) per diluted share. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the registrant's financial performance and operational trends.
View raw filing on EDGAR →The filing discloses that RGC Resources is hosting a conference call to discuss "operating results of the Company's third quarter ending June 30, 2026," with presentation materials furnished as Exhibit 99.1. This is a disclosure of quarterly financial results, which qualifies as an earnings release despite being filed under Item 7.01 (Regulation FD Disclosure) rather than the more typical Item 2.02. The substance—disclosure of Q3 operating results—is material to investors.
View raw filing on EDGAR →The filing discloses a declaration of a quarterly cash dividend of $0.02 per share on common stock, payable September 11, 2026, to shareholders of record as of August 28, 2026. This is a straightforward dividend distribution event. The CEO's statement emphasizes the Board's confidence in financial performance and commitment to shareholder returns, confirming the materiality of this capital allocation decision.
View raw filing on EDGAR →The disclosure details cash distributions to limited partners totaling $0.93 per common unit paid in 2026, plus scheduled distributions for August and September 2026 (including a special distribution of $0.12 per unit), with the October 5, 2026 payment totaling approximately $4.6 million. This is a clear dividend_distribution event involving both regular monthly distributions and special distributions to partnership unit holders, material to investors in the partnership.
View raw filing on EDGAR →